Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)
Biosimulation refers to computer aided simulation of biological processes and systems, an integral part of systems biology used in drug discovery and development. This report will analyze the potential of biosimulation in drug discovery and development. Biosimulation is used across the drug discovery and development program (such as target identification, target validation, lead discovery, lead optimization, preclinical and clinical test).
The global biosimulation market was valued at $432.0 million in 2011 and is expected to reach $1.2 billion by 2017, at a CAGR of 18.50%. Biosimulation in preclinical and clinical stages contributed maximum share (60%) to the global biosimulation market in 2011.
The major driving factor for this market is the cost and time spent on drug discovery and development programs and failure of drug candidates in the late development stages. Pharmaceutical companies around the globe spent around $68 billion in 2011 in drug discovery and development programs, many of the drug discovery and development programs fail in the late stages of the clinical trials, wasting all the years of efforts and money. There is a need for predictive technology which would outlay the outcome of a drug candidate in the discovery stages; biosimulation is one such technology which can bring down the cost on drug discovery and development programmes by focusing on promising lead drug candidates and experiments.
North America is the biggest market for biosimulation followed by Europe. North America, which is the largest drug market in the world contributes one third for the global biosimulation market. Europe is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market is still considered to be in development stages because of non availability of skilled workforce and infrastructure in place.
We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Accelrys (U.S.), Schrodinger (U.S.), Certara (U.S.), Simulation plus (U.S.), Rhenovia (France), ACD/Labs (Canada), CCG (Canada), LeadScope (U.S.), Entelos (U.S.), Genedata (Switzerland), Physiomics (U.K.), Insilico biotechnology (Germany), Insilico biosciences (U.S.), Archimedes (U.S.), Compugen (Israel).
Scope of the report
This research report categorizes global biosimulation market for drug discovery and development on the basis of application and geography; forecasting volume and analyzing trends in the region by application.
On the basis of Applications: The biosimulation market is segmented on the basis of its application in drug discovery and development processes such as: Target identification and validation, lead discovery, optimization, preclinical and clinical trials. Each application is further described in detail in the report with volume and revenue forecasted for each application.
On the basis of Geography: North America, Europe, Asia and ROW.
The global biosimulation market was valued at $432.0 million in 2011 and is expected to reach $1.2 billion by 2017, at a CAGR of 18.50%. Biosimulation in preclinical and clinical stages contributed maximum share (60%) to the global biosimulation market in 2011.
The major driving factor for this market is the cost and time spent on drug discovery and development programs and failure of drug candidates in the late development stages. Pharmaceutical companies around the globe spent around $68 billion in 2011 in drug discovery and development programs, many of the drug discovery and development programs fail in the late stages of the clinical trials, wasting all the years of efforts and money. There is a need for predictive technology which would outlay the outcome of a drug candidate in the discovery stages; biosimulation is one such technology which can bring down the cost on drug discovery and development programmes by focusing on promising lead drug candidates and experiments.
North America is the biggest market for biosimulation followed by Europe. North America, which is the largest drug market in the world contributes one third for the global biosimulation market. Europe is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market is still considered to be in development stages because of non availability of skilled workforce and infrastructure in place.
We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Accelrys (U.S.), Schrodinger (U.S.), Certara (U.S.), Simulation plus (U.S.), Rhenovia (France), ACD/Labs (Canada), CCG (Canada), LeadScope (U.S.), Entelos (U.S.), Genedata (Switzerland), Physiomics (U.K.), Insilico biotechnology (Germany), Insilico biosciences (U.S.), Archimedes (U.S.), Compugen (Israel).
Scope of the report
This research report categorizes global biosimulation market for drug discovery and development on the basis of application and geography; forecasting volume and analyzing trends in the region by application.
On the basis of Applications: The biosimulation market is segmented on the basis of its application in drug discovery and development processes such as: Target identification and validation, lead discovery, optimization, preclinical and clinical trials. Each application is further described in detail in the report with volume and revenue forecasted for each application.
On the basis of Geography: North America, Europe, Asia and ROW.
1 INTRODUCTION
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Need for new tools in drug discovery process
3.3.1.2 Increased spending on healthcare
3.3.1.3 Cost attributed to the traditional drug discovery process
3.3.1.4 Failure of drug candidates in the late development stages
3.3.1.5 Improved computational power
3.3.1.6 Improved modelling & simulation tools
3.3.2 RESTRAINTS
3.3.2.1 Unproven predictive methodology
3.3.2.2 Risk of Potential safe drug failing in biosimulation
3.3.2.3 Lack of standardization
3.3.2.4 Limited knowledge of biological systems & process
3.3.3 CHALLENGES
3.3.3.1 Increasing accuracy in prediction
3.3.3.2 Increasing collaboration/partnership among vendors & pharmaceutical companies
3.3.3.3 Integration of other technologies for better predictive models
3.3.4 TRENDS
3.3.4.1 Drug repositioning
3.3.4.2 In Patient medication
3.3.5 SWOT ANALYSIS
3.3.5.1 Strengths
3.3.5.2 Weakness
3.3.5.3 Opportunities
3.3.5.4 Threats
4 GLOBAL BIOSIMULATION MARKET, BY APPLICATION
4.1 SEGMENTATION BASED ON APPLICATIONS
4.2 APPLICATION IN DRUG DISCOVERY
4.2.1 TARGET IDENTIFICATION
4.2.1.1 Protein structure prediction
4.2.2 TARGET VALIDATION
4.2.2.1 Molecular modeling
4.2.3 LEAD IDENTIFICATION/DISCOVERY
4.2.3.1 De novo Design
4.2.4 LEAD OPTIMIZATION
4.2.4.1 QSAR (Quantitative structure–activity relationship) Models
4.3 APPLICATION IN DRUG DEVELOPMENT
4.3.1 PRE-CLINICAL TESTING
4.3.1.1 ADME/Tox prediction
4.3.1.2 Pharmacokinetic/Pharmacodynamic (PK/PD) models
4.3.2 CLINICAL TRIALS
4.3.2.1 Phase I clinical trial
4.3.2.2 Phase II clinical trial
4.3.2.3 Phase III clinical trial
4.3.3 IN PATIENT VALIDATION
5 CURRENT TRENDS & DEVELOPMENTS
5.1 MODELING AND SIMULATIONS IN PAEDIATRICS DRUG DEVELOPMENT
5.2 MODELLING & SIMULATIONS IN NEGLECTED DISEASES DRUG DEVELOPMENT
5.2.1 DRUG REPOSITIONING
5.2.2 GRID ENABLED DRUG DISCOVERY MODEL
6 GEOGRAPHIC ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA
6.5 REST OF THE WORLD
6.6 TRENDS IN ASIA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 PORTER’S FIVE FORCE ANALYSIS
7.3 MERGERS & ACQUISITIONS
7.4 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES
7.5 NEW PRODUCT LAUNCHES
8 COMPANY PROFILE
8.1 ACCELYRS, INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCTS & SERVICES
8.1.4 STRATEGY
8.1.5 DEVELOPMENTS
8.2 ADVANCED CHEMISTRY DEVELOPMENT (ACD/LABS)
8.2.1 OVERVIEW
8.2.2 PRODUCTS & SERVICES
8.2.3 STRATEGY
8.2.4 DEVELOPMENTS
8.3 ARCHIMEDES, INC.
8.3.1 OVERVIEW
8.3.2 PRODUCTS & SERVICES
8.3.3 DEVELOPMENTS
8.4 CERTARA
8.4.1 OVERVIEW
8.4.2 PRODUCTS & SERVICES
8.4.3 STRATEGY
8.4.4 DEVELOPMENTS
8.5 CHEMICAL COMPUTING GROUP
8.5.1 OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 STRATEGY
8.5.4 DEVELOPMENTS
8.6 COMPUGEN
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCTS & SERVICES
8.6.4 DEVELOPMENTS
8.7 ENTELOS, INC.
8.7.1 OVERVIEW
8.7.2 PRODUCTS & SERVICES
8.7.3 DEVELOPMENTS
8.8 GENEDATA AG
8.8.1 OVERVIEW
8.8.2 PRODUCTS & SERVICES
8.8.3 STRATEGY
8.8.4 DEVELOPMENTS
8.9 IN SILICO BIOSCIENCES, INC.
8.9.1 OVERVIEW
8.9.2 PRODUCTS & SERVICES
8.10 INHIBOX, LTD
8.10.1 OVERVIEW
8.10.2 PRODUCTS & SERVICES
8.10.3 DEVELOPMENTS
8.11 INSILICO BIOTECHNOLOGY AG
8.11.1 OVERVIEW
8.11.2 PRODUCTS & SERVICES
8.11.3 DEVELOPMENTS
8.12 LEADINVENT
8.12.1 OVERVIEW
8.12.2 PRODUCTS & SERVICES
8.13 LEADSCOPE, INC.
8.13.1 OVERVIEW
8.13.2 PRODUCTS & SERVICES
8.13.3 STRATEGY
8.14 MOLECULAR KNOWLEDGE SYSTEMS, INC.
8.14.1 OVERVIEW
8.14.2 PRODUCTS & SERVICES
8.14.3 DEVELOPMENTS
8.15 NIMBUS DISCOVERY LLC
8.15.1 OVERVIEW
8.15.2 PRODUCTS & SERVICES
8.15.3 DEVELOPMENTS
8.16 OPEN EYE SCIENTIFIC SOFTWARE, INC.
8.16.1 OVERVIEW
8.16.2 PRODUCTS & SERVICES
8.16.3 DEVELOPMENTS
8.17 PHYSIOMICS PLC
8.17.1 OVERVIEW
8.17.2 FINANCIALS
8.17.3 PRODUCTS & SERVICES
8.17.4 STRATEGY
8.17.5 DEVELOPMENT
8.18 RHENOVIA PHARMA S.A.S
8.18.1 OVERVIEW
8.18.2 PRODUCTS & SERVICES
8.18.3 STRATEGY
8.18.4 DEVELOPMENTS
8.19 SCHRODINGER
8.19.1 OVERVIEW
8.19.2 FINANCIALS
8.19.3 PRODUCTS & SERVICES
8.19.4 STRATEGY
8.19.5 DEVELOPMENTS
8.20 SIMULATIONS PLUS, INC.
8.20.1 OVERVIEW
8.20.2 FINANCIALS
8.20.3 PRODUCTS & SERVICES
8.20.4 STRATEGY
8.20.5 DEVELOPMENTS
8.21 SYNERGIX LTD
8.21.1 OVERVIEW
8.21.2 PRODUCTS & SERVICES
8.21.3 DEVELOPMENTS
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Need for new tools in drug discovery process
3.3.1.2 Increased spending on healthcare
3.3.1.3 Cost attributed to the traditional drug discovery process
3.3.1.4 Failure of drug candidates in the late development stages
3.3.1.5 Improved computational power
3.3.1.6 Improved modelling & simulation tools
3.3.2 RESTRAINTS
3.3.2.1 Unproven predictive methodology
3.3.2.2 Risk of Potential safe drug failing in biosimulation
3.3.2.3 Lack of standardization
3.3.2.4 Limited knowledge of biological systems & process
3.3.3 CHALLENGES
3.3.3.1 Increasing accuracy in prediction
3.3.3.2 Increasing collaboration/partnership among vendors & pharmaceutical companies
3.3.3.3 Integration of other technologies for better predictive models
3.3.4 TRENDS
3.3.4.1 Drug repositioning
3.3.4.2 In Patient medication
3.3.5 SWOT ANALYSIS
3.3.5.1 Strengths
3.3.5.2 Weakness
3.3.5.3 Opportunities
3.3.5.4 Threats
4 GLOBAL BIOSIMULATION MARKET, BY APPLICATION
4.1 SEGMENTATION BASED ON APPLICATIONS
4.2 APPLICATION IN DRUG DISCOVERY
4.2.1 TARGET IDENTIFICATION
4.2.1.1 Protein structure prediction
4.2.2 TARGET VALIDATION
4.2.2.1 Molecular modeling
4.2.3 LEAD IDENTIFICATION/DISCOVERY
4.2.3.1 De novo Design
4.2.4 LEAD OPTIMIZATION
4.2.4.1 QSAR (Quantitative structure–activity relationship) Models
4.3 APPLICATION IN DRUG DEVELOPMENT
4.3.1 PRE-CLINICAL TESTING
4.3.1.1 ADME/Tox prediction
4.3.1.2 Pharmacokinetic/Pharmacodynamic (PK/PD) models
4.3.2 CLINICAL TRIALS
4.3.2.1 Phase I clinical trial
4.3.2.2 Phase II clinical trial
4.3.2.3 Phase III clinical trial
4.3.3 IN PATIENT VALIDATION
5 CURRENT TRENDS & DEVELOPMENTS
5.1 MODELING AND SIMULATIONS IN PAEDIATRICS DRUG DEVELOPMENT
5.2 MODELLING & SIMULATIONS IN NEGLECTED DISEASES DRUG DEVELOPMENT
5.2.1 DRUG REPOSITIONING
5.2.2 GRID ENABLED DRUG DISCOVERY MODEL
6 GEOGRAPHIC ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA
6.5 REST OF THE WORLD
6.6 TRENDS IN ASIA
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 PORTER’S FIVE FORCE ANALYSIS
7.3 MERGERS & ACQUISITIONS
7.4 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES
7.5 NEW PRODUCT LAUNCHES
8 COMPANY PROFILE
8.1 ACCELYRS, INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCTS & SERVICES
8.1.4 STRATEGY
8.1.5 DEVELOPMENTS
8.2 ADVANCED CHEMISTRY DEVELOPMENT (ACD/LABS)
8.2.1 OVERVIEW
8.2.2 PRODUCTS & SERVICES
8.2.3 STRATEGY
8.2.4 DEVELOPMENTS
8.3 ARCHIMEDES, INC.
8.3.1 OVERVIEW
8.3.2 PRODUCTS & SERVICES
8.3.3 DEVELOPMENTS
8.4 CERTARA
8.4.1 OVERVIEW
8.4.2 PRODUCTS & SERVICES
8.4.3 STRATEGY
8.4.4 DEVELOPMENTS
8.5 CHEMICAL COMPUTING GROUP
8.5.1 OVERVIEW
8.5.2 PRODUCTS & SERVICES
8.5.3 STRATEGY
8.5.4 DEVELOPMENTS
8.6 COMPUGEN
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCTS & SERVICES
8.6.4 DEVELOPMENTS
8.7 ENTELOS, INC.
8.7.1 OVERVIEW
8.7.2 PRODUCTS & SERVICES
8.7.3 DEVELOPMENTS
8.8 GENEDATA AG
8.8.1 OVERVIEW
8.8.2 PRODUCTS & SERVICES
8.8.3 STRATEGY
8.8.4 DEVELOPMENTS
8.9 IN SILICO BIOSCIENCES, INC.
8.9.1 OVERVIEW
8.9.2 PRODUCTS & SERVICES
8.10 INHIBOX, LTD
8.10.1 OVERVIEW
8.10.2 PRODUCTS & SERVICES
8.10.3 DEVELOPMENTS
8.11 INSILICO BIOTECHNOLOGY AG
8.11.1 OVERVIEW
8.11.2 PRODUCTS & SERVICES
8.11.3 DEVELOPMENTS
8.12 LEADINVENT
8.12.1 OVERVIEW
8.12.2 PRODUCTS & SERVICES
8.13 LEADSCOPE, INC.
8.13.1 OVERVIEW
8.13.2 PRODUCTS & SERVICES
8.13.3 STRATEGY
8.14 MOLECULAR KNOWLEDGE SYSTEMS, INC.
8.14.1 OVERVIEW
8.14.2 PRODUCTS & SERVICES
8.14.3 DEVELOPMENTS
8.15 NIMBUS DISCOVERY LLC
8.15.1 OVERVIEW
8.15.2 PRODUCTS & SERVICES
8.15.3 DEVELOPMENTS
8.16 OPEN EYE SCIENTIFIC SOFTWARE, INC.
8.16.1 OVERVIEW
8.16.2 PRODUCTS & SERVICES
8.16.3 DEVELOPMENTS
8.17 PHYSIOMICS PLC
8.17.1 OVERVIEW
8.17.2 FINANCIALS
8.17.3 PRODUCTS & SERVICES
8.17.4 STRATEGY
8.17.5 DEVELOPMENT
8.18 RHENOVIA PHARMA S.A.S
8.18.1 OVERVIEW
8.18.2 PRODUCTS & SERVICES
8.18.3 STRATEGY
8.18.4 DEVELOPMENTS
8.19 SCHRODINGER
8.19.1 OVERVIEW
8.19.2 FINANCIALS
8.19.3 PRODUCTS & SERVICES
8.19.4 STRATEGY
8.19.5 DEVELOPMENTS
8.20 SIMULATIONS PLUS, INC.
8.20.1 OVERVIEW
8.20.2 FINANCIALS
8.20.3 PRODUCTS & SERVICES
8.20.4 STRATEGY
8.20.5 DEVELOPMENTS
8.21 SYNERGIX LTD
8.21.1 OVERVIEW
8.21.2 PRODUCTS & SERVICES
8.21.3 DEVELOPMENTS
LIST OF TABLES
TABLE 1 COST & TIME INVOLVED IN DRUG DISCOVERY PROCESS
TABLE 2 BIOSIMULATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 3 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 4 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 5 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 6 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 7 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 8 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 9 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 10 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 11 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 12 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 13 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 14 MERGERS & ACQUISITIONS, 2009 – 2012
TABLE 15 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES, 2009 – 2012
TABLE 16 NEW PRODUCT LAUNCHES, 2009 – 2012
TABLE 1 COST & TIME INVOLVED IN DRUG DISCOVERY PROCESS
TABLE 2 BIOSIMULATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 3 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 4 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 5 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 6 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 7 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 8 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 9 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 10 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 11 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 12 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 13 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
TABLE 14 MERGERS & ACQUISITIONS, 2009 – 2012
TABLE 15 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES, 2009 – 2012
TABLE 16 NEW PRODUCT LAUNCHES, 2009 – 2012
LIST OF FIGURES
FIGURE 1 MARKET REVENUE FORECAST, 2012 – 2017
FIGURE 2 BUBBLE CHART: REGION WISE MARKET SHARE & GROWTH RATE
FIGURE 3 SEGMENTATION OF BIOSIMULATION MARKET
FIGURE 4 MARKET SHARE ANALYSIS OF MAJOR PLAYERS
FIGURE 5 APPLICATION OF BIOSIMULATION IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 6 MARKET SHARE BY SEGMENTS, 2011
FIGURE 7 MARKET SHARE BY APPLICATION, 2011
FIGURE 8 PROCEDURE OF PROTEIN STRUCTURE PREDICTION
FIGURE 9 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 10 MARKET SHARE OF PROTEIN PREDICTING SOFTWARE & SERVERS, 2011
FIGURE 11 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 12 MARKET SHARE OF MOLECULAR MODELLING SOFTWARE & PROGRAMMES, 2011
FIGURE 13 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 14 MARKET SHARE OF DE NOVO DESIGN SOFTWARE, 2011
FIGURE 15 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 16 MARKET SHARE OF QSAR MODELS, 2011
FIGURE 17 ANALYSIS OF MAIN REASONS FOR ATTRITION IN DRUG DEVELOPMENT
FIGURE 18 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 19 ADME-TOX MARKET SHARE ANALYSIS, 2011
FIGURE 20 PK/PD MODEL REPRESENTATION
FIGURE 21 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 22 PK/PD MARKET SHARE ANALYSIS, 2011
FIGURE 23 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 24 ACCEPTANCE LEVEL OF MODELLING & SIMULATIONS IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 25 MARKET ANALYSIS OF TECHNOLOGIES USED IN DRUG DISCOVERY & DEVELOPMENT
FIGURE 26 MODELLING AND SIMULATION IN PAEDIATRICS DRUG DEVELOPMENT
FIGURE 27 M&S IN PAEDIATRIC DRUG DEVELOPMENT
FIGURE 28 REGIONAL MARKER LIFE CYCLE ANALYSIS
FIGURE 29 BIOSIMULATION MARKET REVENUE GROWTH TREND, BY REGION, 2011& 2017
FIGURE 30 BIOSIMULATION MARKET GROWTH RATE, BY REGION, 2012 – 2017
FIGURE 31 BIOSIMULATION MARKET REVENUE, BY REGION, 2011 – 2017
FIGURE 32 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 33 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 34 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 35 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 36 KEY GROWTH STRATEGIES, 2009 – 2012
FIGURE 37 PORTER’S FIVE FORCE ANALYSIS
FIGURE 1 MARKET REVENUE FORECAST, 2012 – 2017
FIGURE 2 BUBBLE CHART: REGION WISE MARKET SHARE & GROWTH RATE
FIGURE 3 SEGMENTATION OF BIOSIMULATION MARKET
FIGURE 4 MARKET SHARE ANALYSIS OF MAJOR PLAYERS
FIGURE 5 APPLICATION OF BIOSIMULATION IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 6 MARKET SHARE BY SEGMENTS, 2011
FIGURE 7 MARKET SHARE BY APPLICATION, 2011
FIGURE 8 PROCEDURE OF PROTEIN STRUCTURE PREDICTION
FIGURE 9 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 10 MARKET SHARE OF PROTEIN PREDICTING SOFTWARE & SERVERS, 2011
FIGURE 11 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 12 MARKET SHARE OF MOLECULAR MODELLING SOFTWARE & PROGRAMMES, 2011
FIGURE 13 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 14 MARKET SHARE OF DE NOVO DESIGN SOFTWARE, 2011
FIGURE 15 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 16 MARKET SHARE OF QSAR MODELS, 2011
FIGURE 17 ANALYSIS OF MAIN REASONS FOR ATTRITION IN DRUG DEVELOPMENT
FIGURE 18 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 19 ADME-TOX MARKET SHARE ANALYSIS, 2011
FIGURE 20 PK/PD MODEL REPRESENTATION
FIGURE 21 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 22 PK/PD MARKET SHARE ANALYSIS, 2011
FIGURE 23 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 24 ACCEPTANCE LEVEL OF MODELLING & SIMULATIONS IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 25 MARKET ANALYSIS OF TECHNOLOGIES USED IN DRUG DISCOVERY & DEVELOPMENT
FIGURE 26 MODELLING AND SIMULATION IN PAEDIATRICS DRUG DEVELOPMENT
FIGURE 27 M&S IN PAEDIATRIC DRUG DEVELOPMENT
FIGURE 28 REGIONAL MARKER LIFE CYCLE ANALYSIS
FIGURE 29 BIOSIMULATION MARKET REVENUE GROWTH TREND, BY REGION, 2011& 2017
FIGURE 30 BIOSIMULATION MARKET GROWTH RATE, BY REGION, 2012 – 2017
FIGURE 31 BIOSIMULATION MARKET REVENUE, BY REGION, 2011 – 2017
FIGURE 32 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 33 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 34 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 35 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 36 KEY GROWTH STRATEGIES, 2009 – 2012
FIGURE 37 PORTER’S FIVE FORCE ANALYSIS
